2023 ISAKOS Biennial Congress ePoster
Costal Chondrocyte-Derived Pellet-Type Autologous Chondrocyte Implantation vs. Microfracture for Repair of Articular Cartilage Defects
Dae Keun Suh, MD, PhD, Seoul KOREA, REPUBLIC OF
Kyoung-Ho Yoon, MD, PhD, Prof., Seoul KOREA, REPUBLIC OF
Cheol Hee Park, MD, PhD, Seoul KOREA, REPUBLIC OF
Sang-Gyun Kim, MD, PhD, Seoul KOREA, REPUBLIC OF
Jae-Young Park, MD, Seoul KOREA, REPUBLIC OF
Yoon-Seok Kim, MD, Hongcheon KOREA, REPUBLIC OF
Hee Sung Lee, MD, Seoul KOREA, REPUBLIC OF
Sung Hyun Hwang, MD, Seoul KOREA, REPUBLIC OF
Bo Seung Bae, MD, Seoul KOREA, REPUBLIC OF
Kyung Hee University Hospital, Seoul, KOREA, REPUBLIC OF
FDA Status Cleared
Summary
Costal chondrocyte-derived pellet-type autologous chondrocyte implantation for repair of articular cartilage defects
ePosters will be available shortly before Congress
Abstract
Background
Costal chondrocyte-derived pellet-type autologous chondrocyte implantation(CCP-ACI) has been introduced as a new therapeutic option for treatment of articular cartilage defect. We had previously conducted a randomized controlled trial comparing CCP-ACI versus microfracture at 1 year. Patients were followed up at 5 years for clinical and radiological evaluation.
Purpose
To study the efficacy and safety results at 5 years of CCP-ACI versus microfracture.
Methods
This article describes the 5-year follow-up of a previous prospective clinical trial that compared the results of CCP-ACI versus microfracture at 1-year follow-up. Of the 30 patients from the CCP-ACI group that were described in the previous study, 25 were followed-up. Clinical outcomes score and magnetic resonance imaging was performed at last follow-up.
Results
MOCART scores improved significantly from baseline to 5 years postoperatively only in the CCP-ACI group (P < 0.0001). The MOCART scores in the CCP-ACI group was significantly greater than that in the MFx group at 5 years (70.9 vs 26.7, P < 0.0001). The Lysholm score and KOOS score in the CCP-ACI group was significantly greater than that in the MFx group at 5 years (84.5 vs 64.9 and 390.9 vs 303.0, P = 0.023 and P = 0.038, respectively).
Conclusion
Treatment of cartilage defects with CCP-ACI yielded better clinical and radiologic outcome compared to microfracture at 5 years.